CN Patent
CN113286884A — 新型cas12b酶和系统
Assigned to Massachusetts Institute of Technology · Expires 2021-08-20 · 5y expired
What this patent protects
本公开提供了用于靶向核酸的系统、方法和组合物。特别是,本发明提供了非天然存在的或工程化的RNA靶向系统,所述系统包含新型的靶向RNA的Cas12b效应蛋白和至少一种靶向核酸组分,如指导RNA或crRNA。
USPTO Abstract
本公开提供了用于靶向核酸的系统、方法和组合物。特别是,本发明提供了非天然存在的或工程化的RNA靶向系统,所述系统包含新型的靶向RNA的Cas12b效应蛋白和至少一种靶向核酸组分,如指导RNA或crRNA。
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.